John J Alam

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Topics

Blood Brain Barrier

Acute Ischemic Stroke

Top Venues

Molecular neurodegeneration

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

John J Alam, Paul Maruff, Susan Doctrow, Hui-May Chu, Jennifer Conway, Stephen N Gomperts, Charlotte E Teunissen
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies. Neurology (2023)
John J Alam, Ralph A Nixon
Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come. Molecular neurodegeneration 18 (1) (2023)
John J Alam, Ralph A Nixon
Correction: Drug development targeting degeneration of the basal forebrain cholinergic system: its time has come. Molecular neurodegeneration 18 (1) (2023)
John J Alam, Ralph A Nixon
Disease-modifying pharmacological approaches to correcting basal forebrain cholinergic neuronal (BFCN) dysfunction and degeneration. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 47 (1) (2022)
Ying Jiang, John J Alam, Stephen N Gomperts, Paul Maruff, Afina W Lemstra, Ursula A Germann, Philip H Stavrides, Sandipkumar Darji, Sandeep Malampati, James Peddy, Cynthia Bleiwas, Monika Pawlik, Anna Pensalfini, Dun-Sheng Yang, Shivakumar Subbanna, Balapal S Basavarajappa, John F Smiley, Amanda Gardner, Kelly Blackburn, Hui-May Chu, Niels D Prins, Charlotte E Teunissen, John E Harrison, Philip Scheltens, Ralph A Nixon
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration. Nature communications 13 (1) (2022)
John J Alam, Michael Krakovsky, Ursula Germann, Aharon Levy
Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level. PloS one 15 (12) (2020)